# Cypherpunk Technologies Inc.: overview CYPH · Nasdaq · CIK 1509745 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cyph.md) · [Financials](/companies/cyph/financials.md) · [Filings](/companies/cyph/filings.md) · [Insiders](/companies/cyph/insiders.md) Latest reported revenue: [$375.0k](/filings/0001104659-23-036239.md) for Q4 FY2021, three months to 2021-12-31, from the 10-K filed Mar 24, 2023 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-23-036239). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.44)](/filings/0001104659-25-109827.md) | not reported | [(0.37)](/filings/0001104659-26-060662.md) | [(0.40)](/filings/0001104659-26-094449.md) | [(0.08)](/filings/0001104659-25-109827.md) | not reported | [(0.46)](/filings/0001104659-26-060662.md) | [0.18](/filings/0001104659-26-094449.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,500](/filings/0001104659-23-036239.md) | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(2761.7%)](/filings/0001104659-23-036239.md) | not reported | not reported | not reported | not reported | | Net margin | % | [(2705.8%)](/filings/0001104659-23-036239.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.47)](/filings/0001104659-23-036239.md) | [(4.82)](/filings/0001410578-24-000218.md) | [(3.98)](/filings/0001410578-25-000454.md) | [(1.81)](/filings/0001104659-26-028566.md) | [0.07](/filings/0001104659-26-028566.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cyph/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2021-09-24 | [BeiGene, Ltd.](/insiders/1651308.md) | 10% owner | Purchase (P) | 2,543,800 | $2.85 | $7.2m | [Form 4](/filings/0001651308-21-000197.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.4m | 3,887,574 | | Added +2,069,160 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.6m | 2,622,823 | | Added +280,649 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $1.0m | 1,701,926 | | New +1,701,926 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $718.8k | 1,173,737 | | Added +602,669 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $689.9k | 1,127,366 | | Added +956,298 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $512.0k | 836,153 | | New +836,153 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $390.8k | 638,329 | | Added +607,671 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $355.8k | 583,200 | Call | Added +3,700 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $349.7k | 571,345 | | Added +274,259 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $316.0k | 516,113 | | Added +376,000 | ## Recent filings [All 615 filings](/companies/cyph/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-22 | 11:05 ET | [8-K](/filings/0001104659-26-109463.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-109463 | | 2026-09-02 | 20:30 ET | [8-K](/filings/0001104659-26-104753.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-104753 | | 2026-08-19 | 22:55 ET | [SCHEDULE 13D/A](/filings/0002085726-26-000002.md) | Ownership report, active investor, amended | 0002085726-26-000002 | | 2026-08-18 | 11:05 ET | [8-K](/filings/0001104659-26-098120.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-098120 | | 2026-08-12 | 11:16 ET | [10-Q](/filings/0001104659-26-094449.md) | Quarterly report, period 2026-06-30 | 0001104659-26-094449 | | 2026-08-12 | 11:10 ET | [8-K](/filings/0001104659-26-094445.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-094445 | | 2026-07-21 | 20:05 ET | [8-K](/filings/0001104659-26-085399.md) | 3.01 Delisting notice | 0001104659-26-085399 | | 2026-06-22 | 20:05 ET | [8-K](/filings/0001104659-26-076364.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-076364 | | 2026-05-26 | 12:00 ET | [8-K](/filings/0001104659-26-066019.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-066019 | | 2026-05-14 | 11:10 ET | [8-K](/filings/0001104659-26-060686.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-060686 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-028566.md), filed Mar 16, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1509745 - Tickers: CYPH - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.